Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Pesquisa Study Connect
  • NCT06869551

Recruiting

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis - IM011-1071

Atualizado: 17 junho, 2025   |   ClinicalTrials.gov

Imprima o Resumo

CONSIDERANDO ESTE ESTUDO?
Imprima esta página e o guia de estudo para ajudá-lo a conversar com seu médico.
Use o guia de estudo para navegar no processo de participação em um estudo clínico. Entenda os principais fatores a serem considerados antes de decidir e faça perguntas para sua equipe de saúde.
Imprimir esta página IM011-1071
Baixar o guia

SELECIONAR IDIOMA

Detalhes do estudo

  • Phase 3

    Fase

  • Gênero(s)

  • 5-17

    Faixa etária

  • 24

    Localização(ões)

  • Recruiting

Opções de tratamento

Braços de tratamento do Estudo
INTERVENÇÃO ATRIBUÍDA
Experimental: Arm A
Drug: Deucravacitinib
Placebo Comparator: Arm B
Drug: Deucravacitinib Other: Placebo

Principais critérios de elegibilidade

Inclusion Criteria - Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). - Participants must have at least three joints that are affected by arthritis. - Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems. Exclusion Criteria - Participants must not have been diagnosed with JPsA before 5 years of age. - Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA, - Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months. - Other protocol-defined Inclusion/Exclusion criteria apply.

É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas

Tem dúvidas? Envie-nos um email.

Tem dúvidas?
Envie-nos um email.